Clinical Trial Update: Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS) [Phase 2]

View source ↗

Summary

Phase 2 trial update of lenalidomide plus darbepoetin in patients with low-intermediate risk myelodysplastic syndromes. The study was terminated and results wer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Lenalidomide (lenalidomide)
• darbepoetin alfa (darbepoetin alfa)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2011-04-26